Abatacept for giant cell arteritis treatment
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 3 trial tests abatacept to treat giant cell arteritis (GCA), a blood vessel inflammation that can cause headaches and vision risk. It’s for people with newly diagnosed or returning (relapsing) GCA with active symptoms in the last 8 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with giant cell arteritis (new or returning).
- Your GCA symptoms are active within the past 8 weeks.
- You can follow the study plan and attend all follow-up visits.
- If you could become pregnant, you must use reliable birth control during the study.
- You must be able to sign written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a special MRI (picture scan) can evaluate giant cell arteritis when it’s newly suspected and symptoms started recently. It may help doctors confirm the diagnosis and decide on treatment sooner by comparing MRI findings with standard testing like biopsy or ultrasound.
This study looks at whether people with suspected giant cell arteritis (a type of blood vessel inflammation) have a certain kind of blood cell change called clonal hematopoiesis. It aims to help doctors better understand the disease and could lead to improved care.
This study checks whether different MRI scanning details can better help doctors diagnose giant cell arteritis. If you’re being sent for an injected MRI because GCA is suspected, your scan results may help improve how future diagnoses are made.
This Phase 3 study compares how two standard steroid dose-reduction (tapering) schedules work for people with giant cell arteritis. It aims to see which taper approach controls the disease while reducing problems from long-term steroid use.
This trial tests whether the drug upadacitinib can help people with giant cell arteritis (GCA) that affects the large blood vessels, such as the aorta. It is for those who have not responded to, cannot tolerate, or cannot use another treatment called tocilizumab.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
Hear when a new Giant Cell Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.